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Hematopoietic stem cell transplantation and mesenchymal stromal cell therapy are currently
under investigation as novel therapies for inflammatory bowel diseases. Hematopoietic stem
cells (HSC) are thought to repopulate the immune system and reset the immunological response
to luminal antigens. Mesenchymal stromal cells (MSC) are cells that have the capacity to
differentiate into wide variety of distinct cell lineages and suppress immune responses in vitro
and in vivo. Recent results from animal models and early human experience in graft-versus-host
disease but also Crohn's Disease suggest that ex vivo expanded MSCs may have clinically useful
immunomodulatory effects.
© 2008 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.KEYWORDS
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Despite the improvement in medical therapy of inflamma-
tory bowel disease (IBD) with the introduction of anti-TNFα
compounds, disease control remains hard to achieve in many
patients. Adult stem cells are currently under investigation
for a variety of inflammatory disorders. This article reviews
the potential of stem cells therapy for IBD. We will
summarize reports on hematopoietic stem cell transplanta-
tion (HSCT) in inflammatory bowel disease and we will
introduce the possible advantages of mesenchymal stromal
cell (MSC) therapy.
1.1. What is a stem cell?
A classical definition of a stem cell is a cell that has the
capacity for self-renewal and the ability to give rise to one or
more types of differentiated progeny.1,2 Self-renewal is
defined as the ability of a cell to proliferate while it maintains
its proliferation and differentiation potential. Stem cells are
known to exist in different tissues but their frequency, exact
role and identity are generally not well understood. Both in
animal models and in patients, it appears that bone marrow
derived cells play a role in the healing process following
intestinal injury3 and that theymay contribute to regeneration
of various components mucosa.4–6 The bone marrow contains
at least two types of stem cells. One population consists of
CD34 positive hematopoietic stem cells committed to differ-
entiate into all blood cell types, including the myeloid and
lymphoid lineages. A second population of stem cells remains
less well characterized. These non-hematopoietic stem cells
are thought to support hematopoiesis and are variously known
as mesenchymal stem cells, marrow stromal cells and more
recently, mesenchymal stromal cells, all designated by the
acronym MSC.7
2. Hematopoietic stem cell transplantation
Although more than 50 years ago HSCT was introduced as a
treatment for injury, it is now principally used for hemato-
logic and lymphoid cancers.8 Evidence that HSCT is an
effective treatment for autoimmune diseases come from
animal models9,10 and case reports from HSCTrecipients with
coexistent autoimmune disease.11 Ever since, autologous
HSCT has been performed in more than 700 patients with
autoimmune disease.12 The most frequent indications being
systemic sclerosis, multiple sclerosis, rheumatoid arthritis
and systemic lupus erythematosus.
HSCT includes conditioning (high dose chemotherapy,
total body irradiation and/or anti-lymphocyte antibodies)
which completely eliminates bone marrow cells of the hostfollowed by the infusion of either autologous or allogeneic
stem cells. The HSCs are either directly harvested from the
marrow or mobilized from marrow or blood and harvested by
apheresis. High dose immune ablation is an intensive
treatment with risks of severe complications which on rare
occasions have been fatal. In autologous transplantation, the
individual's own hematopoietic stem cells are harvested to
be returned after conditioning. The graft is typically
depleted of T cells to avoid the reinfusion of autoreactive T
cells. In allogeneic transplantation, the HSCs come from a
donor, usually a HLA matched sibling. In addition to the
complications associated with conditioning, allogeneic HSCT
is associated with a much higher transplant-related morbid-
ity, such as graft-versus-host disease, aplastic anemia, and
hematological malignancies, and also a higher mortality (15–
25% vs. 3–5%13) due to a considerable risk on graft-versus-
host disease. In view of the risks related to allogeneic
transplantation most patients treated for autoimmune
disease have received autologous transplants.
2.1. Hematopoietic stem cell transplantation in IBD
patients for other indications
2.1.1. Autologous HSCT
The possibility that autologous HSCT could be an effective
treatment for IBD was suggested by the improvement of the
clinical course of disease in patients with CD that received
autologous transplantation for other indications.14–18 The
first published abstract dates from 1993 and described two
year clinical remission in two patients with active IBD treated
with autologous HSCT for breast cancer.14 Long term clinical
remission after autologous HSCT was reported in a patient
with clinical disease control of CD up to 7 years following
transplantation for non-Hodgkin lymphoma.16 A similar
result was obtained in a 30 year old patient with a ten year
history of severe CD who developed Hodgkin's disease and
remained in complete treatment-free remission of both
diseases 3 years after autologous HSCT19 and in a patient who
had normal findings during ileo-colonoscopy at 1, 2, 3 and
5 years after transplantation for acute myeloid leukemia.18
2.1.2. Allogeneic HSCT
Similar to the first experience with autologous HSCT in IBD,
the effect of allogeneic HSCTon IBD was initially described in
patients treated for hematological malignancies. The first
case report was published in 1998 and described a 35 year old
male free of symptoms and signs of CD 8 years post allogeneic
marrow transplantation for acute leukemia.20 A second
report in the same year described 6 patients that underwent
allogeneic transplantation for leukemia between 1962 and
1982.21 In this report, 5 out 6 patients had active CD at time
of transplantation. One patient died of septic complications
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mained free of disease activity for more than 1 year post-
transplantation. Only one out of these five patients
relapsed during follow up with a duration of up to 15 years
post transplantation. Interestingly, the only patient that
developed a mixed donor-host hematopoietic chimerism
following allogeneic HSCT continued to have active CD
before death by suicide. In a retrospective study by
Ditschkowski et al., 10 out of 11 patients remained free of
symptoms following allogeneic HSCT for hematological
malignancy with a median follow-up time of 34 months.22
In a case report published recently,23 a 41 year old man
underwent allogeneic HSCT for lymphoma. Following
transplantation his bowel symptoms ceased and he was
able to stop all immunosuppressive drugs. Eighteen months
after transplantation colonoscopy showed no evidence of
Crohn's disease activity. Remission of ulcerative colitis
following allogeneic HSCT has also been described.24 Two
patients, each with a long history of psoriasis and ulcer-
ative colitis, received an allogeneic HSCT for leukemia
and remained in full remission 424 and 12 years25 after
transplantation.
The coincidental treatment of IBD with both autologous
and allogeneic HSCT increased the interest in the possibility
that stem cell transplantation could be of value in IBD.
Autologous HSCs are infused only to shorten the post-HSCT
neutropenic interval, in contrast with allogeneic HSCT in
which the recipient's immune and hematologic system is
replaced with that of a healthy donor without the genetic
predisposition to Crohn's disease. In this light it has been
proposed that the risk of disease recurrence may be higher
after autologous HSCT.262.2. Early studies on HSCT specifically for CD
The first reports of autologous HSCTspecifically given for the
treatment of Crohn's disease were published in 2003 and
concerned five patients with severe disease activity refrac-
tory to conventional treatment and treatment with anti-
TNFα antibody.27–29 No serious transplantation related
complications were reported and all patients entered clinical
remission but some of the colonoscopies showed persistent
mild inflammation up to 1 year post-transplantation. A larger
phase 1 study on twelve patients with chronic active, re-
fractory CD also suggested that autologous HSCT can have a
beneficial effect on CD activity. Besides fever, the autologous
HSCT was well tolerated by the patients. After 15 months
only one patient developed a recurrence of active CD. All
others maintained a clinical and drug-free remission but
similar to the patients described in the reports above with
persisting nonsymptomatic histologic and/or radiologic
evidence of CD.30 Adverse effects included hematemesis
from a Mallory–Weiss tear, a prolonged febrile course,
C. difficle-induced diarrhea, and diarrhea after an upper
respiratory infection.
Our own experience consists of three autologous HSCT in
patients with refractory CD (Zelinkova et al., DDW 2005).
Our protocol includes a mobilization phase with cyclopho-
sphamide 4 g/m2 and granulocyte colony-stimulating factor
(G-CSF) 2dd 5 μg/kg. Prior to transplantation, immune ab-
lation is achieved using cyclophosphamide 50 mg/kg/day(4 days), anti-thymocyte globulin 30 mg/kg/day (3 days)
and prednisolone 500 mg (3 days).
Autologous HSCTwas offered to one patient suffering from
extensive refractory small bowel disease, failing combina-
tion therapy of immunosuppressives and infliximab and for
whom surgery was considered not to be an attractive
alternative as it would most likely result in a short bowel
syndrome. Although an initial clinical response after mobi-
lization was observed, the patient experienced a clinical and
endoscopic relapse within weeks. During the HSCT patient
developed an allergic reaction to anti-thymocyte globulin
that resolved with a standard treatment and the HSCT was
completed successfully. In week 8 of the follow-up after
HSCT, the patient was clinically in complete remission,
gaining weight and without need for a supplementary
parenteral nutrition. Endoscopically, a clear improvement
of the inflammatory lesions was observed. As expected,
residual strictures persisted. Two additional patients with
refractory CD, unresponsive to anti-TNF therapy and experi-
mental anti-CD3 (visilizumab) therapy, unwilling to undergo
proctocolectomy, underwent successful (partial) autologous
HSCT. One male patient with a complicated history of a
refractory CD that failed infliximab and experimental anti-
CD3 therapy underwent the mobilisation phase, had a partial
response, and was subsequently transplanted. He regained
full remission, both clinically and endoscopically. We
restarted azathioprine therapy, and during a follow-up of
2 years the patient remains in remission. Our third patient is
a female with a similar history, a completely refractory CD
including failure of anti-TNF therapy. After the mobilisation
phase she went in complete remission and, as a result, was
not transplanted. She has now been in complete clinical and
endoscopic remission for 2 years including an uncomplicated
pregnancy.
This last patient is a good example of role of the immu-
nosuppressive/cytoreductive effects of the conditioning
regimen in the treatment success of HSCT. To evaluate the
efficacy of HSC mobilisation followed by high dose immune
ablation and autologous stem cell transplantation versus HSC
mobilisation only, a multicenter, prospective, randomised
phase III study has been initiated by the European Crohn's and
Colitis Organisation (ECCO) in collaboration with the Eur-
opean Group for Blood and Marrow Transplantation (EBMT).31
2.3. Potential risks of hematopoietic stem cell
transplantation
HSCT may be an effective treatment for CD but is also
associated with a high morbidity and mortality.32 In 390
patients undergoing autologous HSCT for various autoim-
mune diseases a mobilization associated mortality of 1.5%
and an overall procedure related mortality of 9% were
found.33 Early toxicity is related to direct organ damage
either from the agents used or due to infection and bleeding
during the 10–12 days of bone marrow aplasia following the
immunosuppressive conditioning period. Late toxicity
relates to malignancy development due to the chemother-
apy and/or radiation exposure. In addition, HSCT is
associated with complications such as veno-occlusive
disease of the liver and acute and chronic graft-versus-
host disease.34 Although HSCT seems a reasonably successful
Table 1 Three minimal criteria to identify MSCs as defined in the ISCT position statement66
MSCs must
1. Adhere to plastic when maintained in culture
2. Be able to differentiate into at least osteoblasts, adipocytes and chondroblasts under standard in vitro differentiating conditions
(demonstrated by well established staining protocols)
3. Be positive (≥95%) for CD105, CD73 and CD90 and be negative (≤2% positive) for haematopoietic antigens like CD45, CD34 and
markers for monocytes, macrophages (CD14 or CD11b) and B cells (CD79α or CD19). HLA-DR molecules should not be expressed on
MSCs unless they are stimulated, e.g. by IFNγ.
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mortality rate of HSCT for autoimmune diseases, this
treatment should only be considered to rare cases of CD.
HSCT could be considered as a last resort for treatment in
patients with debilitating disease refractory to all immuno-
suppressive drugs, including the different anti-TNFα com-
pounds now available for treatment, and in patients in
which surgery is not a treatment option.
3. Mesenchymal stromal cell transplantation
HSCT is thought to result in clinical remission in CD due to the
combination of the immunosuppressive conditioning regimen
and the replacement of the derailed lamina propria immune
cells that maintain the disease. A novel emerging stem cell
treatment may offer the benefit of immunosuppression with-
out the need for conditioning chemotherapy, even when
given as allogeneic transplant.
3.1. Mesenchymal stromal cells
Friedenstein and colleagues were the first to identify an
adherent, fibroblast-like population of cells in bone mar-
row.35 These cells are now known under various names but
will be termed mesenchymal stromal cells or be referred to
by acronym MSC throughout this review. MSCs turned out to
have stem cell like properties. The first MSCs that have been
described were bone marrow derived non-hematopoietic
cells since they did not express hematopoietic cell lineage
markers such as CD34, CD45 and CD14.36,37 Indeed, MSCs
have now been isolated from a wide variety of tissues
including fat, periosteum, hair follicles and scalp subcuta-
neous tissues, muscle, synovium, synovial fluid and period-
ontal ligament,38–47 placenta, umbilical cord blood, fetal
blood, bone marrow, liver, lung and spleen48–50 suggesting
that MSCs are not unique to the bone marrow environment
but in stead widely distributed in vivo51. Depending on the
specific culture conditions used, these cells have the
potential to generate a wide variety of mesenchymal cell
lineages, including bone,52 cartilage,53 fat,54 muscle,55
tendon,56 stroma57 and cardiomyocytes.58–60 In vitro and in
vivo studies have also indicated the capability of MSCs to
differentiate into neural precursor,61,62 and hepatocyte63
like cells. Very important for their potential clinical
application is that MSCs are easily isolated as they adhere
to plastic and are capable of substantial proliferation
and expansion in culture.37 Additionally, MSCs can be
cryopreserved with no loss of phenotype or differentiation
potential.64,654. Definition
In the absence of an agreed standardized marker, MSCs have
been defined by a combination of phenotypic and functional
characteristics. To further homogenize studies on MSCs
the Mesenchymal and Tissue Stem Cell Committee of the
International Society for Cellular Therapy (ISCT) has intro-
duced three minimal criteria to identify human MSC66
[Table 1. Three minimal criteria to identify MSCs as defined
in the ISCT position statement].
4.1. Preclinical data on MSCs
Immunomodulatory functions of MSCs were examined in vitro
by coculturing them with purified subpopulations of immune
cells and report that MSCs suppress several functions of naïve
and memory T cells,67–72 B cells67,71,73 and natural killer
cells71,74,75 as well as the differentiation, maturation and
function of dendritic cells.76–78 Furthermore they have been
shown to alter the cytokine secretion profile of the host
immune cells to shift from a pro-inflammatory phenotype
toward a more anti-inflammatory or tolerant phenotype
in vitro.79 Di Nicola et al. found that MSCs reversibly inhibited
T cell activation by several different stimuli in vitro. In their
experiments cell to cell contact was only partially responsible
for these effects, in transwell experiments it was shown that
the observed inhibition dependedmainly on the production of
soluble factors.80
Animal studies indicate that, similar to their immunosup-
pressive capacities in vitro, MSCs also display immunosup-
pressive capacities in vivo. Murine MSCs have been used to
successfully treat a T-cell mediated experimental model of
multiple sclerosis in mice81 and administration of allogeneic
MSCs led to prolonged skin graft survival when compared to
control animals in immunocompetent baboons.70 Systemi-
cally infused MSCs first show a wide-ranging distribution
followed by homing to injured tissues58,82 (including the
gut83–85) where they may participate in tissue repair.83,85 In
addition, following intravenous infusion MSCs can home to
the bone marrow where they can persist in for an extended
period of time.84 However, only a small percentage of the
infused MSCs are traceable, and the fate of the rest remains
unknown.
Although thought tobemostly immuneprivileged,MSCsmay
under certain conditions also be subject to immune rejection.
Data from a murine model suggest that, in nonmyeloablated
hosts, allogeneic MSCs are able to mount a T-cell memory
response and consequently are eliminated.86 Comparable loss
of immune privilege has been reported by others.87
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Due to their immunosuppressive properties and their role in
tissue repair MSCs seem a promising tool in immunoregula-
tory and regenerative cell therapy in a variety of human
diseases. Furthermore, a major advantage of MSCs over HSCT
is that infusion of MSCs is nonmyeloablative, thus without
total body irradiation. The initial clinical trials were in
patients with osteogenesis imperfecta,88 followed by trials in
which the immunosuppressive effects of the MSCs were used
either to reduce the incidence of graft-versus-host disease
after allogeneic HSCT89 or as treatment of active disease,
including GvHD of the gut refractory to conventional
immunosuppressive therapy.90 The effects of MSCs on GvHD
suggested the potential use of MSCs in the treatment of other
autoimmune disorders.
5. MSCs in Crohn's disease
Recently, the results have been published of a phase I clinical
trial on cell therapy, in which autologous MSC transplantation
was used for the treatment of fistulizing CD. In this study,
nine fistulas in four patients were inoculated with autologous
adipose tissue-derived MSCs. After 8 weeks 75 percent these
fistulas were considered healed and no adverse effects were
observed in any patient.91 A phase II trial on autologous
adipose tissue-derived MSCs is underway.92
In a press release, the American company Osiris Ther-
apeutics, Inc. reported encouraging results of a phase II study
in patients with moderate to severe CD unresponsive to
standard pharmacologic interventions using Prochymal™, a
type of MSCs derived from the bonemarrow of normal healthy
adult volunteer donors.93 All patients were reported to show
a significant reduction in disease activity by day 28 upon
infusion of stem cells.94 Unfortunately the trial has not yet
been published in a peer reviewed journal for evaluation of
these important claims made in the media. Osiris Therapeu-
tics is reportedly enrolling patients for a phase III trial.95
5.1. Potential risks of mesenchymal stromal cell
transplantation
More than 100 patients have received MSCs and though acute
toxicity appears low, little is known about long-term unwanted
side effects.96 Reports showed that MSCs stimulate the growth
of cancers in mice97,98 and promote metastasis in mice.99
Although an increased risk on tumor formation has never been
confirmed in humans, patients should be thoroughly screened
before MSC administration as the cells might enhance the
growth of unknown cancer. Another concern is that extensively
in vitro expanded stem cells may be prone to malignant trans-
formation. In fact, human MSCs derived from adipose tissues
have been shown to undergo spontaneous transformation after
being passaged for a long time (4–5 months) in in vitro culture.
However, no such abnormalities where reported by Bernardo
et al. who proliferated bone marrow derived MSCs from 10
healthy donors for up to 44 weeks until reaching either sene-
scenceorpassage25.100 Accordingly, it is of great importance to
carefully characterize MSCs passaged in vitro both phenotypi-
cally and karyotypically to maximize safety for the recipient.6. Conclusion
The clinical course of Crohn's disease can not be adequately
controlled in a substantial group of patients despite treat-
ment with an extensive repertoire of immunosuppressives,
anti-TNF therapy and surgical interventions. Severe com-
plications of the disease include peri-anal fistulizing
disease.
Autologous HSCT has been evaluated for sever refractory
cases. This treatment can be successfully used as a last resort
in an attempt to control debilitating disease is associated
with significant morbidity and mortality related to che-
motherapy. The use of MSCs derived from either bone
marrow or adipose tissue could be an alternative appraoch.
This treatment does not work by replacement of the disease
causing inflammatory cells in the lamina propria but is
believed to involve active suppression of these immune cells
by as of yet uncharacterized MSC derived signals at the site of
inflammation. If effective, the big advantage of the use of
MSCs is the fact that this treatment does not involve con-
ditioning chemotherapy. MSCs are currently under active
investigation as a treatment option for Crohn's Disease and
encouraging preliminary data seem to support the further
study of this new approach.
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